The purpose of this study is to evaluate how well Cemiplimab works when given before a procedure called a sentinel lymph node biopsy, which is a test to check if cancer has spread to nearby lymph nodes. The study will measure whether this treatment helps prevent the presence of tiny cancer spread in the lymph nodes. Patients in this study will have already had their primary tumor removed and will be scheduled for the lymph node biopsy. The study will also look at how long patients remain free from cancer coming back, how long patients survive, and how the treatment affects their quality of life.

During the study, patients will receive two cycles of treatment before their lymph node biopsy. The study will collect tissue samples from the original tumor site and from the lymph node biopsy to examine how the treatment affects the cancer. Safety will be monitored throughout the study by tracking any side effects that occur. The study will also compare outcomes between patients who receive Cemiplimab and those who receive placebo, looking at factors such as whether cancer returns, survival rates, and overall well-being using questionnaires.

The purpose of this study is to test how well a short course of combined chemotherapy and immunotherapy works when given before surgery in patients with Merkel Cell Carcinoma. The treatment involves one cycle of therapy followed by an operation to remove the tumor. During the treatment, patients will receive the medications through intravenous infusions at specified doses.

After the surgery is completed, doctors will examine the removed tumor tissue to determine if any cancer cells remain. The study will also look at how safe the treatment is and how it affects patients’ quality of life. Researchers will collect blood samples and tumor tissue to study how the treatment affects the cancer cells and the body’s immune system.

Participants in the study will receive the treatment over a period of time, with regular monitoring to assess how their body responds to the medication. The study will look at both the local effects at the site of the tumor and the overall effects on the body. The goal is to determine the best dose of BT-001 and to see how well it works when used with pembrolizumab. Some participants may receive a placebo as part of the study to help compare the effects of the actual treatment.

Throughout the study, participants will undergo various assessments to monitor their health and the progression of their cancer. This includes regular check-ups and tests to ensure the treatment is safe and to measure its impact on the cancer. The study aims to provide valuable information on the potential benefits of combining BT-001 with pembrolizumab for treating these challenging types of cancer.

The purpose of this study is to compare the effects of continuing standard immunotherapy with a reduced dose of the same treatment. The medications being studied include Pembrolizumab, Durvalumab, Avelumab, Nivolumab, Dostarlimab, Atezolizumab, and Cemiplimab. These medications are given through an intravenous infusion, which means they are administered directly into the bloodstream through a vein. Some patients will receive the standard dose of these medications, while others will receive a reduced dose every three months.

The study will last for up to three years, during which time patients will continue to receive their assigned treatment. The main goal is to see if the reduced dose is as effective as the standard dose in keeping the cancer from getting worse. Patients will have regular check-ups and assessments to monitor their health and the progress of their cancer. The study will also look at other factors, such as the quality of life and any side effects experienced by the patients. This research aims to find the best way to use immunotherapy to treat cancer effectively while minimizing side effects.